Publications by authors named "W F Barker"
Background: Mild cognitive impairment (MCI) is a clinical diagnosis representing early symptom changes with preserved functional independence. There are multiple potential etiologies of MCI. While often presumed to be related to Alzheimer's disease (AD), other neurodegenerative and non-neurodegenerative causes are common.
View Article and Find Full Text PDFAttrition is a significant methodological concern in longitudinal studies. Sample loss can limit generalizability and compromise internal validity. Wave one ( = 346) and wave two follow-ups ( = 196) of the 1Florida ADRC clinical core were examined using a 24-month visit window.
View Article and Find Full Text PDFArticle Synopsis
- Health information technology (health IT) has significantly transformed healthcare in the U.S. by enhancing data exchange, e-prescribing, and patient access to health info.
- The study assesses advancements in health IT adoption, focusing on how it aligns with the goals of improving healthcare data access and sharing, as outlined by the Office of the National Coordinator for Health IT.
- Findings show a massive increase in electronic health record usage, with 70% of hospitals now interoperable and 92% of prescribers using e-prescribing, facilitating easier access to personal health information for patients and caregivers.
Neuroimaging and biofluid biomarkers provide a proxy of pathological changes for Alzheimer's disease (AD) and are useful in improving diagnosis and assessing disease progression. However, it is not clear how race/ethnicity and different prevalence of AD risks impact biomarker levels. In this narrative review, we survey studies focusing on comparing biomarker differences between non-Hispanic White American(s) (NHW), African American(s) (AA), Hispanic/Latino American(s) (HLA), and Asian American(s) with normal cognition, mild cognitive impairment, and dementia.
View Article and Find Full Text PDFArticle Synopsis
- Antimicrobial resistance (AMR) is severely limiting the effectiveness of antibiotics, especially against Gram-negative bacteria, making global health increasingly at risk.
- Researchers highlight that the rising resistance to colistin, a last-line antibiotic for treating multi-drug resistant infections, is particularly concerning.
- The study presents new adjuvants, including IMD-0354 and novel benzimidazole compounds, which effectively restore colistin sensitivity in resistant bacterial infections in mouse models, showing low toxicity and promising results in reducing bacterial load.